

Sebastian Bauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/454448/publications.pdf>

Version: 2024-02-01

230
papers

11,670
citations

44042

48
h-index

32815

100
g-index

244
all docs

244
docs citations

244
times ranked

11325
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸ Ga-FAPI PET Prospective Observational Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 89-95.	2.8	58
2	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
3	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	3.2	32
4	INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib. <i>Journal of Clinical Oncology</i> , 2022, 40, 359881-359881.	0.8	14
5	New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. <i>Current Oncology Reports</i> , 2022, 24, 151-159.	1.8	7
6	5-ALA-mediated fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model: preclinical in vivo qualification analysis as a fluorescence-guided surgery agent in Orthopedic Oncology. <i>Journal of Orthopaedic Surgery and Research</i> , 2022, 17, 34.	0.9	5
7	Reversible occlusion of the pulmonary vasculature by transarterial embolisation with degradable starch microspheres: preclinical assessment in a human isolated lung perfusion model. <i>European Radiology Experimental</i> , 2022, 6, 6.	1.7	0
8	Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region – Data From the Prospective Registries ProReg and KiProReg. <i>Frontiers in Oncology</i> , 2022, 12, 805051.	1.3	2
9	Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 1087-1097.	3.2	22
10	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2307-2320.	0.8	24
11	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. <i>BMC Cancer</i> , 2022, 22, 511.	1.1	6
12	Gastrointestinal Stromal Tumor. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 431-446.	0.6	4
13	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 –CREATE–Trial. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5689.	1.8	2
14	KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 11514-11514.	0.8	2
15	Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2022, 40, 101-101.	0.8	3
16	A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11586-TPS11586.	0.8	0
17	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	3.2	45
18	Gene expression-based prediction of pazopanib efficacy in sarcoma. <i>European Journal of Cancer</i> , 2022, 172, 107-118.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Evaluation of ¹⁸ F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. <i>Journal of Nuclear Medicine</i> , 2021, 62, 348-353.	2.8	9
20	Is the high-performance thermoplastic polyetheretherketone indicated as a clasp material for removable dental prostheses?. <i>Clinical Oral Investigations</i> , 2021, 25, 2859-2866.	1.4	10
21	Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. <i>Oncologist</i> , 2021, 26, e863-e873.	1.9	28
22	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	1.9	20
23	Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution Study. <i>Journal of Surgical Research</i> , 2021, 260, 149-154.	0.8	7
24	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. <i>Cancer Discovery</i> , 2021, 11, 108-125.	7.7	47
25	Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. <i>Oncologist</i> , 2021, 26, e639-e649.	1.9	29
26	Reply to E. Younger et al, V. Sharma et al, and M. Uchihara et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 864-865.	0.8	0
27	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. , 2021, 9, e001458.		26
28	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. <i>Cancer</i> , 2021, 127, 2666-2673.	2.0	15
29	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Cancers, 2021, 13, 1223.	1.7	15
30	Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. <i>European Journal of Cancer</i> , 2021, 145, 132-142.	1.3	75
31	The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 191.	1.2	25
32	GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors. <i>Frontiers in Genetics</i> , 2021, 12, 663272.	1.1	16
33	Ewing Sarcomaâ€”Diagnosis, Treatment, Clinical Challenges and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1685.	1.0	101
34	Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma. <i>BMC Cancer</i> , 2021, 21, 375.	1.1	7
35	Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11536-11536.	0.8	0
36	Tropomyosin receptor kinases in sarcomas â€” of joy and despair. <i>Current Opinion in Oncology</i> , 2021, 33, 336-344.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. <i>Radiology and Oncology</i> , 2021, 55, 347-353.	0.6	5
38	Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 2753.	1.7	7
39	Pharmacokineticâ€“pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. <i>British Journal of Cancer</i> , 2021, 125, 687-698.	2.9	19
40	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
41	The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3735-3747.	1.2	3
42	Early and Next-Generation KIT/PDGFR Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 672500.	1.3	35
43	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the ^{INVICTUS} Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
44	Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	2.8	64
45	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous ^{KIT/PDGFR} Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25
46	Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology. <i>Sarcoma</i> , 2021, 2021, 1-10.	0.7	6
47	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
48	Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 683-691.	0.7	2
49	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020, 16, 4251-4264.	1.1	43
50	Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma. <i>European Journal of Cancer</i> , 2020, 124, 152-160.	1.3	24
51	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewingâ€™s Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. <i>Clinical Orthopaedics and Related Research</i> , 2020, 478, 290-302.	0.7	45
52	Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations. <i>Histopathology</i> , 2020, 76, 814-821.	1.6	18
53	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3555-3564.	0.8	56
54	Targeting Her2-insYVMA with Covalent Inhibitorsâ€™A Focused Compound Screening and Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11725-11755.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Fatal swelling of the groin â€“ Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1165-1168.	0.4	2
56	Multimodality treatment including surgery for primary pulmonary sarcoma: Size does matter. Journal of Surgical Oncology, 2020, 122, 506-514.	0.8	8
57	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. JAMA Oncology, 2020, 6, 1241.	3.4	111
58	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 923-934.	5.1	224
59	Germline <i>SDHB</i> inactivating mutation in gastric spindle cell sarcoma. Genes Chromosomes and Cancer, 2020, 59, 601-608.	1.5	4
60	Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2020, 21, 935-946.	5.1	186
61	Predicting outcome of epilepsy surgery in clinical practice: Prediction models vs. clinical acumen. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 79-83.	0.9	6
62	Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS). Journal of Cancer Research and Clinical Oncology, 2020, 146, 953-960.	1.2	10
63	Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.. Journal of Clinical Oncology, 2020, 38, 11503-11503.	0.8	3
64	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. Journal of Clinical Oncology, 2020, 38, 11535-11535.	0.8	8
65	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. Journal of Clinical Oncology, 2020, 38, 11536-11536.	0.8	3
66	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4th-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. Journal of Clinical Oncology, 2020, 38, 11539-11539.	0.8	3
67	Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.. Journal of Clinical Oncology, 2020, 38, 11533-11533.	0.8	0
68	Abstract 821: Comprehensive genomic analysis of rare cancers: Results of the MASTER precision oncology trial of the German Cancer Consortium. , 2020, , .		0
69	Abstract 3005: Comprehensive profile of platelet derived growth factor receptor alpha (PDGFRA) mutations in gastrointestinal stromal tumors. , 2020, , .		0
70	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer, 2019, 19, 794.	1.1	20
71	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€” TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	1.9	22
72	S1â€“ Leitlinie Dermatofibrosarcoma protuberans (DFSP) â€“ Update 2018. JDDG - Journal of the German Society of Dermatology, 2019, 17, 663-668.	0.4	6

#	ARTICLE	IF	CITATIONS
73	Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting. <i>Oncology Research and Treatment</i> , 2019, 42, 629-635.	0.8	3
74	Desmoplastic small round cell tumors: Multimodality treatment and new risk factors. <i>Cancer Medicine</i> , 2019, 8, 527-542.	1.3	39
75	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet</i> , 2019, 394, 478-487.	6.3	273
76	S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 663-668.	0.4	18
77	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	2.9	33
78	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). <i>Clinical Sarcoma Research</i> , 2019, 9, 3.	2.3	26
79	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	2.3	21
80	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. <i>Nature Communications</i> , 2019, 10, 1635.	5.8	64
81	¹⁸ F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1537-1542.	2.8	19
82	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2019, 120, 612-620.	2.9	109
83	New therapeutic agents in gastrointestinal stromal tumours. <i>Current Opinion in Oncology</i> , 2019, 31, 322-328.	1.1	13
84	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. <i>Chemical Science</i> , 2019, 10, 10789-10801.	3.7	25
85	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
86	Predictive Biomarkers and Targeted Therapies in Sarcomas. , 2019, , 475-492.		0
87	What is the best therapy for grossly resected synovial sarcoma? Experience of the CWS Study Group.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10042-10042.	0.8	0
88	Abstract 1686: Comprehensive genomic and transcriptomic profiling of gastrointestinal stromal tumors. , 2019, , .		0
89	Abstract 468: Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium. , 2019, , .		0
90	Abstract 2723: Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases. <i>Head and Neck Pathology</i> , 2018, 12, 511-516.	1.3	25
92	Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27011.	0.8	22
93	Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2018, 142, 2080-2093.	2.3	21
94	Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). <i>Cancer</i> , 2018, 124, 1449-1454.	2.0	32
95	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	5.8	197
96	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 CREATE™. <i>Annals of Oncology</i> , 2018, 29, 758-765.	0.6	67
97	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 CREATE™. <i>European Journal of Cancer</i> , 2018, 94, 156-167.	1.3	35
98	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	1.9	27
99	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	20
100	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	0.8	107
101	Dramatic Response of a PD-L1 Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	1.5	16
102	Bone sarcomas: ESMO/ESMO/ESMO/PaedCan/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
103	Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. , 2018, 6, 111.		122
104	Gastrointestinal stromal tumours: ESMO/ESMO/ESMO/PaedCan/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
105	Soft tissue and visceral sarcomas: ESMO/ESMO/ESMO/PaedCan/EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
106	Options for treating different soft tissue sarcoma subtypes. <i>Future Oncology</i> , 2018, 14, 25-49.	1.1	35
107	The Interdisciplinary Diagnosis and Treatment of Intraocular Tumors. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 106-111.	0.6	13
108	A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2018, 100, 17-26.	1.3	85

#	ARTICLE	IF	CITATIONS
109	Translational insights into gastrointestinal stromal tumor and current clinical advances. <i>Annals of Oncology</i> , 2018, 29, 2037-2045.	0.6	33
110	Abstract 4336: Integrative genomic and transcriptomic analysis of leiomyosarcoma. , 2018, , .		2
111	Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma. <i>Cancer Research</i> , 2018, 78, CT009-CT009.	0.4	11
112	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	0.8	16
113	Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11506-11506.	0.8	11
114	Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11507-11507.	0.8	3
115	First prospective observational study in diffuse-type tenosynovial giant cell tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11560-11560.	0.8	2
116	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11570-11570.	0.8	2
117	Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 191-191.	0.8	3
118	Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018, 36, 580-580.	0.8	1
119	Validation of the new UICC classification (8th ed.) for the staging of GIST in the TKI era.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23517-e23517.	0.8	0
120	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11540-11540.	0.8	1
121	Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21531-e21531.	0.8	0
122	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2361-2372.	2.9	43
123	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). <i>European Journal of Cancer</i> , 2017, 76, 60-67.	1.3	88
124	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. <i>Nature Communications</i> , 2017, 8, 14674.	5.8	53
125	Lower limb function and quality of life after ILP for soft-tissue sarcoma. <i>World Journal of Surgical Oncology</i> , 2017, 15, 84.	0.8	15
126	Preclinical models for translational sarcoma research. <i>Current Opinion in Oncology</i> , 2017, 29, 275-285.	1.1	11

#	ARTICLE	IF	CITATIONS
127	Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the EuroEWING 99 trial. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26524.	0.8	4
128	Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1823-1831.	3.3	43
129	Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. <i>JAMA Oncology</i> , 2017, 3, 602.	3.4	141
130	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8801-8815.	2.9	7
131	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285.	2.9	33
132	Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. <i>International Journal of Hematology</i> , 2017, 106, 765-776.	0.7	32
133	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , 2017, 87, 147-163.	1.3	108
134	Sustained Mutant KIT Activation in the Golgi Complex Is Mediated by PKC- ζ in Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 845-856.	3.2	12
135	Pulmonary metastasectomy for sarcoma—Essen experience. <i>Journal of Thoracic Disease</i> , 2017, 9, S1278-S1281.	0.6	10
136	Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with <i>TP53</i> wt advanced tumors. <i>Cancer Research</i> , 2017, 77, CT150-CT150.	0.4	4
137	Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model. , 2017, , .		7
138	Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11011-11011.	0.8	16
139	STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9511-9511.	0.8	12
140	Abstract LB-287: Identification of patients at risk for tumor predisposition syndromes based on the evaluation of sporadic cancer exome sequencing data: experiences from the NCT/DKTK MASTER program. , 2017, , .		0
141	Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts). <i>Annals of Oncology</i> , 2016, 27, vii74.	0.6	1
142	Inhibition wirkstoffresistenter Mutationsvarianten der Rezeptortyrosinkinase EGFR. <i>Angewandte Chemie</i> , 2016, 128, 11069-11073.	1.6	4
143	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour — Does it increase the risk for tumour cell seeding and recurrence?. <i>European Journal of Cancer</i> , 2016, 59, 128-133.	1.3	39
144	Molecular subtypes of gastrointestinal stromal tumor requiring specific treatments. <i>Current Opinion in Oncology</i> , 2016, 28, 331-337.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 10909-10912.	7.2	54
146	HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 59-71.	1.3	9
147	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1629-1637.	6.3	610
148	The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. <i>Investigational New Drugs</i> , 2016, 34, 159-167.	1.2	5
149	Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). <i>Annals of Surgical Oncology</i> , 2016, 23, 1924-1927.	0.7	58
150	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 244-250.	0.8	174
151	Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE", 2016, , .		4
152	Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study "NCT01692496". <i>Journal of Clinical Oncology</i> , 2016, 34, 11039-11039.	0.8	11
153	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4516-4516.	0.8	5
154	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22520-e22520.	0.8	7
155	Adjuvant chemotherapy in high-risk liposarcomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11036-11036.	0.8	0
156	Abstract 377: Novel mTOR inhibitor MLN0128 inhibits imatinib-resistant GIST more potently than rapalogues by abrogating AKT and 4EBP1 activation. , 2016, , .		0
157	Covalent Allosteric Kinase Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 10313-10316.	7.2	87
158	Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor. <i>PLoS ONE</i> , 2015, 10, e0120531.	1.1	14
159	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. <i>Oncotarget</i> , 2015, 6, 36041-36052.	0.8	103
160	miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. <i>Molecular Oncology</i> , 2015, 9, 1421-1433.	2.1	71
161	Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. <i>Drugs</i> , 2015, 75, 1323-1334.	4.9	32
162	Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function. <i>Leukemia and Lymphoma</i> , 2015, 56, 3189-3197.	0.6	22

#	ARTICLE	IF	CITATIONS
163	Overcoming the proliferation rate paradox: Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205.. Journal of Clinical Oncology, 2015, 33, 2528-2528.	0.8	1
164	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	0.8	22
165	EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).. Journal of Clinical Oncology, 2015, 33, TPS10576-TPS10576.	0.8	0
166	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research, 2014, 20, 5745-5755.	3.2	137
167	Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Annals of Oncology, 2014, 25, 719-724.	0.6	92
168	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120, 2325-2333.	2.0	65
169	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. British Journal of Cancer, 2014, 110, 1155-1162.	2.9	42
170	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib â€“ Analysis of prognostic factors (EORTC-STBSG collaborative study). European Journal of Surgical Oncology, 2014, 40, 412-419.	0.5	125
171	Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistance.. Journal of Clinical Oncology, 2014, 32, 10555-10555.	0.8	2
172	Brain metastases in sarcoma patients: Incidence and outcome.. Journal of Clinical Oncology, 2014, 32, 10591-10591.	0.8	7
173	First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein.. Journal of Clinical Oncology, 2014, 32, 2564-2564.	0.8	9
174	Abstract 3375: Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumors. , 2014, , .		0
175	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry, 2013, 56, 5757-5772.	2.9	17
176	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. Annals of Surgical Oncology, 2013, 20, 2937-2943.	0.7	190
177	Liposarcomas. Hematology/Oncology Clinics of North America, 2013, 27, 939-955.	0.9	36
178	The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-Î±: a comparison with the whole group of resected soft tissue sarcomas. World Journal of Surgical Oncology, 2013, 11, 185.	0.8	9
179	Pemetrexed in patients with refractory soft tissue sarcoma: A non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. Investigational New Drugs, 2013, 31, 167-174.	1.2	3
180	Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma. Human Pathology, 2013, 44, 2266-2274.	1.1	12

#	ARTICLE	IF	CITATIONS
181	Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2013, 39, 61-67.	0.5	22
182	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. <i>European Journal of Cancer</i> , 2013, 49, 3076-3082.	1.3	26
183	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	6.3	1,144
184	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013, 49, 1027-1031.	1.3	69
185	DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3661-3670.	0.4	68
186	Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age. <i>International Journal of Oncology</i> , 2013, 43, 23-28.	1.4	13
187	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST.. , 2013, , .		4
188	Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10509-10509.	0.8	1
189	In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10510-10510.	0.8	5
190	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>Annals of Oncology</i> , 2012, 23, 2763-2770.	0.6	61
191	Growth patterns of lung metastases from sarcoma: prognostic and surgical implications from histology. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 15, 612-617.	0.5	20
192	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1265.	3.8	832
193	Intimal sarcoma of the pulmonary artery with unusual findings: a case report. <i>Clinical Research in Cardiology</i> , 2012, 101, 397-401.	1.5	19
194	p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors. <i>PLoS ONE</i> , 2012, 7, e37776.	1.1	46
195	Abstract 3855: Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumors. , 2012, , .		0
196	Abstract 1824: Functional characterization of DOG1 in Gastrointestinal Stromal Tumors (GIST). , 2012, , .		0
197	Postoperative FDG-PET/CT staging in GIST: Is there a benefit following R0 resection?. <i>European Journal of Radiology</i> , 2011, 80, 670-674.	1.2	9
198	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. <i>Lancet Oncology, The</i> , 2011, 12, 1045-1052.	5.1	212

#	ARTICLE	IF	CITATIONS
199	Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. <i>Current Opinion in Oncology</i> , 2011, 23, 367-372.	1.1	17
200	Growth patterns of lung metastases from sarcomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 213-219.	1.4	16
201	Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF- α and melphalan. <i>Journal of Surgical Oncology</i> , 2011, 103, 371-379.	0.8	37
202	A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 457, 623-625.	1.4	2
203	MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions. <i>Tumor Biology</i> , 2010, 31, 157-163.	0.8	15
204	Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell Tumours. <i>European Urology</i> , 2010, 57, 679-687.	0.9	47
205	Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells. <i>Cancer Research</i> , 2010, 70, 150-159.	0.4	37
206	211 Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimetic. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 69-70.	2.2	1
207	Prognostic relevance of soluble human leukocyte antigen- β and total human leukocyte antigen class I molecules in lung cancer patients. <i>Human Immunology</i> , 2010, 71, 489-495.	1.2	59
208	Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2009, 69, 6941-6950.	0.4	82
209	Evaluation of 47 Soft Tissue Sarcoma Resection Specimens after Isolated Limb Perfusion with TNF- α and Melphalan: Histologically Characterized Improved Margins Correlate with Absence of Recurrences. <i>Annals of Surgical Oncology</i> , 2009, 16, 676-686.	0.7	29
210	Abstract C154: Targeting the MDM2/p53 pathway in gastrointestinal stromal tumors: Therapeutic potential. , 2009, , .		0
211	Abstract C152: Therapeutic potential of histone deacetylase inhibitors in human liposarcomas. , 2009, , .		0
212	Docetaxel and Gemcitabine in the Treatment of Soft Tissue Sarcoma – A Single-Center Experience. <i>Onkologie</i> , 2008, 31, 11-16.	1.1	18
213	Cytomegalovirus Drives Acute Myeloid Leukemia Cells in Apoptosis and Reduces Thereby Markedly the Risk for Relapse after Transplant. <i>Blood</i> , 2008, 112, 3301-3301.	0.6	0
214	The challenge of opportunities: how far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors?. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 619-622.	0.8	1
215	Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II Study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2007, 43, 1017-1022.	1.3	29
216	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. <i>Oncogene</i> , 2007, 26, 7560-7568.	2.6	232

#	ARTICLE	IF	CITATIONS
217	555 POSTER Small-molecule inhibitors of HSP90 in IM-resistant gastrointestinal stromal tumors. European Journal of Cancer, Supplement, 2006, 4, 168.	2.2	0
218	Soft tissue sarcoma. Update on Cancer Therapeutics, 2006, 1, 385-402.	0.9	3
219	Locally advanced and metastatic sarcoma (adult type) including gastrointestinal stromal tumors. Critical Reviews in Oncology/Hematology, 2006, 60, 112-130.	2.0	17
220	Heat Shock Protein 90 Inhibition in Imatinib-Resistant Gastrointestinal Stromal Tumor. Cancer Research, 2006, 66, 9153-9161.	0.4	244
221	Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. International Journal of Cancer, 2005, 117, 316-325.	2.3	160
222	Complete Remission With Imatinib in Metastatic Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2005, 23, 6800-6801.	0.8	12
223	Optimization of Gene Transfer into Neonatal Rat Cardiomyocytes and Unmasking of Cytomegalovirus Promoter Silencing. DNA and Cell Biology, 2005, 24, 381-387.	0.9	15
224	Gemcitabine in the Treatment of Soft Tissue Sarcomas. Oncology Research and Treatment, 2004, 27, 180-186.	0.8	9
225	Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. Journal of Nuclear Medicine, 2004, 45, 357-65.	2.8	219
226	Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemotherapy and Pharmacology, 2003, 51, 261-265.	1.1	73
227	Rational promoter selection for gene transfer into cardiac cells. Journal of Molecular and Cellular Cardiology, 2003, 35, 823-831.	0.9	17
228	Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. Anti-Cancer Drugs, 2002, 13, 847-849.	0.7	22
229	Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib. Oncotarget, 0, 7, 41390-41403.	0.8	22
230	Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0